TG Therapeutics launched its multiple sclerosis drug BRIUMVI in January 2023, with positive market feedback and significant revenue. The company has strong barriers to entry and patent protection for ...
TG Therapeutics and Rhizen Pharmaceuticals Announce Global Agreement for Development and Commercialization of Novel PI3K Delta Selective Inhibitor, TGR-1202 IND Filing Expected Fourth Quarter 2012 ...
MaxCyte, Inc. announced a strategic platform license agreement with TG Therapeutics, a biopharmaceutical company specializing in treatments for B-cell diseases. Under this agreement, TG Therapeutics ...
NEW YORK, Aug. 16, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TG Therapeutics) (OTCBB:TGTX) and Rhizen Pharmaceuticals S A (Rhizen) today announced that the companies have entered into an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback